title: [Therapy of bronchitis. Successful single-dosage treatment with N-acetylcysteine, results of an administration surveillance study in 3,076 patients].
abstract: The efficacy and safety of N-acetylcysteine prescribed in general practice were investigated.
  
  
  METHODS
  open, non-controlled surveillance study conducted at 744 centers.
  
  
  METHODS
  3,076 patients suffering from bronchitis.
  
  
  METHODS
  600 mg N-acetylcysteine (Fluimucil-Long, Inpharzam Germany), administered as a single daily dose.
  
  
  METHODS
  evaluation of coughing, amount and quality of sputum, expectoration, dyspnea, compliance and tolerance.
  
  
  RESULTS
  impressive improvement of the symptom complex, good compliance. Adverse reactions were reported in 45 patients (rate: 1.5%).
  
  
  CONCLUSIONS
  treatment of chronic and acute bronchitis with the mucolytic agent N-acetylcysteine administered once daily, proved to be both effective and well tolerated.
authors.affiliation: Inpharzam GmbH, Gräfelfing.
authors.forename: H H
authors.initials: HH
authors.lastname: Gerards
authors.forename: U
authors.initials: U
authors.lastname: Vits
mesh_terms: D000111:Acetylcysteine / Q000008:administration & dosage*; D000284:Administration, Oral; D001991:Bronchitis / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects
chemical_list: D000111:Acetylcysteine
vernacular_title: Therapie der Bronchitis. Erfolgreiche Behandlung mit N-Acetylcystein als Einmalgabe, Ergebnisse einer Anwendungsbeobachtung bei 3,076 Patienten.